register

Medical

Diabetes doubles risk of certain cancers – new report

Health Industry Hub | May 27, 2020 |

Medical News: Australians living with type 2 diabetes have a 60% higher chance of developing dementia than those without diabetes, and are twice as likely to develop some types of cancer, according to a new report analysing the full impact of the condition.

Released yesterday by the Baker Heart and Diabetes Institute, The Dark Shadow of Type 2 Diabetes report shines light on high-risk areas that are becoming increasingly recognised as complications of diabetes.

The latest national snapshot of type 2 diabetes shows a better approach is needed to address the wider health risks for the 1.5 million Australians currently living with type 2 diabetes, especially the growing number of those under 40 who may live with the disease for decades.

The report’s lead author and Head of Clinical Diabetes and Population Health at the Baker Institute, Professor Jonathan Shaw said diabetes increased the risk of numerous other diseases that most people may not understand were linked.

Register FREE & join 22,000+ industry professionals in reading the latest industry news & engaging content from Health Industry Hub, the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.

“This is what we are calling ‘the dark shadow of type 2 diabetes’, as it can cast a much wider shadow than many realise,” Professor Shaw said.

A recent meta-analysis involving data from two million people showed those living with type 2 diabetes had a 60% greater risk of developing dementia compared to people without diabetes, with women more at risk than men.

Professor Shaw said people with type 2 diabetes were also more likely to develop many types of cancer.

“They are two to three times more likely to develop pancreatic cancer – one of the most deadly cancers, are twice as likely to develop liver or endometrial cancer, have a 50% higher chance of getting bowel cancer and a 20% greater risk of breast cancer,” he said.

You may also like PRIME Awards 2020 call for entries – the only awards program dedicated to recognising excellence within Australian healthcare communications, is now open for entries.

“Increased cancer risk is of particular concern for the growing number of people under 40 living with type 2 diabetes. This group saw a significant increase in deaths from cancer between 2000 and 2011.”

On average, a 45 year old person with diabetes can expect to live six years less than a person free of diabetes, and Professor Shaw said many of these earlier deaths were due to heart disease.

“Heart disease is still the biggest killer of people with type 2 diabetes, and our report shows that heart failure is a leading cause,” he said.

“People with type 2 diabetes are up to eight times more likely to suffer from heart failure, compared to those without diabetes.”

But Professor Shaw said the report also highlighted recent advances around the world showing that some of the newer diabetes medications had the potential to significantly reduce the number of people with diabetes who develop heart and kidney disease.

“In addition to controlling blood sugar levels, it is essential Australians living with type 2 diabetes are supported to keep blood pressure and cholesterol at healthy levels.”

Researchers at the Baker Institute are currently working to understand more about diabetes and how to prevent some of its devastating effects through large-scale research projects, including the PREDICT study.


News & Trends - MedTech & Diagnostics

APHA and MTAA lobbying shapes Health Minister’s decision on General Use Items, ensuring continued patient access

Health Industry Hub | May 1, 2024 |

MedTech & Diagnostics News: The Australian Private Hospitals Association (APHA), Medical Technology Association of Australia (MTAA), Catholic Health Australia and […]

More


News & Trends - Pharmaceuticals

BMS' first-in-class therapy for heart disease PBS listed, set to 'change management'

BMS’ first-in-class therapy for heart disease PBS listed, set to ‘change management’

Health Industry Hub | May 1, 2024 |

Pharma News: Australia’s first cardiac myosin inhibitor for treating symptomatic hypertrophic cardiomyopathy (HCM) has been listed on the Pharmaceutical Benefits […]

More


News & Trends - Pharmaceuticals

New dose of AbbVie's psoriasis drug halves injection frequency for patients

New dose of AbbVie’s psoriasis drug halves injection frequency for patients

Health Industry Hub | May 1, 2024 |

Pharma News: AbbVie’s biologic treatment, Skyrizi (risankizumab), for severe plaque psoriasis is now available on the Pharmaceutical Benefits Scheme (PBS) […]

More


News & Trends - MedTech & Diagnostics

China accused of unfair bias in global medical device procurement

China accused of unfair bias in global medical device procurement

Health Industry Hub | May 1, 2024 |

MedTech & Diagnostics News: The European Commission has initiated an inquiry into China’s procurement practices of medical devices, citing alleged […]

More


This content is copyright protected. Please subscribe to gain access.